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Abstract
We have previously reported that ADP ribosylation factor like 2 (Arl2), a small GTPase, content influences microtubule
dynamics and cell cycle distribution in breast tumor cells, as well as the degree and distribution of phosphorylated P53. Here
we show, in two different human breast adenocarcinoma models, that Arl2 content has a major impact on breast tumor cell
aggressivity both in vitro and in vivo. Cells with reduced content of Arl2 displayed reduced contact inhibition, increased
clonogenic or cluster formation as well as a proliferative advantage over control cells in an in vitro competition assay. These
cells also caused larger tumors in SCID mice, a phenotype which was mimicked by the in vivo administration of siRNA
directed against Arl2. Cells with increased Arl2 content displayed reduced aggressivity, both in vitro and in vivo, with
enhanced necrosis and were also found to contain increased PP2A phosphatase activity. A rt-PCR analysis of fresh human
tumor breast samples suggested that low Arl2 expression was associated with larger tumor size and greater risk of lymph
node involvement at diagnosis. These data underline the role of Arl2, a small GTPase, as an important regulator of breast
tumor cell aggressivity, both in vitro and in vivo.
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Introduction
Arl2 is a GTPase belonging to the ADP ribosylation factor
(ARF) family [1,2].Severalgenetic studiessuggestthat Arl2 plays
a role in MT dynamics [3–5]. In mammalian cells, Bhamidipati
et al. have demonstrated direct binding between Arl2 and tubulin
binding cofactor D (TBC-D), a protein involved in tubulin
folding [6]. TBC-D interacts with beta tubulin and contributes to
the production of polymerizable tubulin heterodimers. TBC-D
can also induce the dissociation of soluble alpha/beta heterodi-
mers [7–10]. Binding of Arl2 to TBC-D inhibits the heterodi-
mer-dissociating activity of TBC-D [6]. More recently, it has
been reported that Arl2 inhibited TBC-D-dependent cell
dissociation from the monolayer and disassembly of the apical
complex [11].
The entire cytosolic pool of Arl2 is complexed with TBC-D and
with the heterotrimeric protein phosphatase 2A (PP2A) [12]. PP2A
is one of the major serine/threonine phosphatases of mammalian
cells. It is composed of three subunits: a regulatory A subunit
(PP2Aa), various types of regulatory B subunits (PP2Ab) and a
catalytic C subunit (PP2Ac). By its involvement in different signal
transduction pathways, PP2A plays a crucial role in the regulation
of several fundamental cell processes such as cell cycle progression
[13], DNA replication [14], apoptosis [15] and protein synthesis.
PP2A is considered to behave as a tumor suppressor protein [14].
Mutations affecting PP2A genes have been found in lung, breast
and colon carcinoma [16,17], as well as in cervical, ovarian,
gastric and nasopharyngeal carcinomas. These mutations fre-
quently consist in deletions in the 11q23 region that encodes the A
subunit [16,17]. Furthermore, inhibitors of PP2A such as okadaic
acid or microcystin-LR are known to promote cell proliferation
and tumorigenesis [12,18,19].
Using breast adenocarcinoma derived MCF7 and MDA-MB
231 cells expressing different levels of Arl2, we have shown that
alterations of cellular Arl2 protein content were associated with
modifications of polymerization-competent 2alpha/beta tubulin
heterodimer levels resulting in altered MT dynamic properties
and with modifications of mitotic progression as well as with
modifications of the content, localization and activity of PP2Ac
with no significant changes in PP2Ac mRNA levels [20]. We also
showed that Arl2 content was associated with the degree and
distribution of phosphorylatedP 5 3 ,i np a r t i c u l a rp h o s p h o r -
ser15-P53, a form which was preferentially bound to microtu-
bules [21].
In this study, we show that Arl2 content is a major determinant
of aggressive phenotype and tumorigenicity in two different breast
cancer cell models, and low Arl2 expression levels appear to be
correlated with enhanced aggressivity in the clinic.
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Contact inhibition of cancer cells is dependent on Arl2
expression levels
To study the contact inhibition of the cell lines expressing
different levels of Arl2 we have evaluated their respective
proliferation rates at confluence using phase contrast microscopy,
MTT assays and flow cytometry analyses. For these experiments
the cellular seeding concentrations were adjusted according to
morphological differences of these cell lines previously described
[20]. The biggest cells (MA+ and MdaA+) were seeded at a 30%
lower concentration whereas the smallest cells (MA- and MdaA-)
were seeded at a 30% higher concentration than the respective
control cells (MP and MdaP). Phase contrast microscopy
observations were used to analyse the cell distribution in Petri
dishes (Figure 1a). MA- cells presented a heterogeneous surface
occupation with some unoccupied spaces along with high cellular
density regions (Figure 1a). Conversely MP, and most notably
MA+ cells, occupied available space more evenly with a
homogeneous distribution. In addition MA- cells were able to
form multi-layers while MP and MA+ grew only in mono-layers,
suggesting that MA- cells had lost contact inhibition (Figure 1a).
The proliferation rates were evaluated using MTT assays at 3, 5
and 6 days post seeding. Three days of culture corresponded to the
confluence conditions for the three cell lines (Figure 1b). The
proliferation rates of both MA- and MP were higher than that of
MA+ whatever the time of culture (p,0.05). The proliferation rate
of MA- and MP cells were very similar until 5 days of culture
whereas that of MA- cells was significantly increased (p,0.05)
compared to that of MP cells after 5 days of culture. Finally flow
cytometry analysis (Figure 1b) showed that the ratio of cells in S-
G2/M phase at confluence versus cells in exponential growth was
Figure 1. Arl2 content alterations induce modification of proliferation and contact inhibition behavior of cancer cells. A: Upper: MA-,
MP and MA+ cells were visualized after MTT incubation and before dissolvation of formazan crystals (purple dishes) to observe cell surface
occupation. Formazan crystals were then dissolved and optic density (OD) measured to obtain the control of cells seeding (in arbitrary units). Lower:
Phase contrast microscopy observations of MA-, MP and MA+ cells. B: Left: Means of proliferation rates of MA2, MP and MA+ cells evaluated by MTT
assay expressed in optic density units per day. Right: Means of percentages of confluent cells versus non-confluent cells in S+G2-M phases evaluated
by flow cytometry. Bars represent standard deviations. Statistical significance was determined using Student’s t test (p,0.05). C: Coculture cell
competition assay using different fluorescent vital cell linker dyes, PKH 67 (green) for MP cells and PKH 26 (red) for MA-. Distributions of each cellular
population were followed using a fluorescent microscope from day 1 to day 3 after cell seeding (representative images). D: Means of proliferation
rates of MA2, MP and MA+ cells incubated with vehicle (DMSO) or with cantharidic acid (CA), evaluated by MTT assay expressed in optic density units
(OD units) per day. Bars represented standard deviations. Statistical significance was determined using Student’s t test.
doi:10.1371/journal.pone.0007478.g001
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(+22%, p,0.05) in MA- cells in comparison to that of control MP
cells. Similar results were obtained for MDA-MB 231 derived
models (data not shown). These data confirmed that cells with
reduced Arl2 content continued to grow at confluence whereas
cells with increased Arl2 content were particularly sensitive to
contact inhibition.
Co-culture experiments with MP and MA- cells were performed
using specific fluorescent linker dyes to follow each cell population
(Figure 1c). After 3 days of co-culture, MA- cells (red fluorescent
dye) have proliferated more quickly than MP cells (green
fluorescent dye) under confluent conditions, confirming the strong
proliferative behavior of MA- cells, and its relative growth
advantage over control cells. Similar results were obtained using
a green fluorescent dye for MA- cells and a red dye for MP cells
(dye swap experiment, data not shown).
Altogether these results showed that, at confluence, cells
expressing high levels of Arl2 (MA+ and MdaA+) displayed a
stronger growth arrest with increased contact inhibition whereas
cells with reduced Arl2 content (MA- and MdaA-) did not seem to
undergo growth arrest and maintained growth ability even at
confluence.
Since Arl2 interacts with PP2A and the content of Arl2
influences PP2A activity [20], we sought to determine whether the
proliferation rates of the different cell lines could be related to
PP2A activity. Growth rates of each cell line were measured in the
presence of cantharidic acid, a well characterized inhibitor of
PP2A. In the presence of cantharidic acid at a dose selectively
inhibiting PP2A (IC50 for PP2A activity =40 nM and for PP1
=473 nM, manufacturer’s indications) (Figure 1d), the growth rate
of MA+ cells was significantly enhanced (+30–70%, p,0,05)
whereas those of MA- and MP cells were not significantly
modified. This result suggests that the proliferation rate is related
to PP2A activity, since cells with the highest Arl2 and PP2A
contents were the most prone to proliferate in the presence of a
PP2A inhibitor.
Effect of Arl2 content on three-dimensional cell growth
Experiments using soft agar and soft agar complemented with
30% Matrigel (extracellular matrix) were performed in order to
distinguish between anchorage-free growth ability (soft agar) and
clonogenic behavior (soft agar+Matrigel) (Figure 2a). No signifi-
cant differences were observed between MA-, MP and MA+ cells
grown in soft agar alone. However, in the soft agar complemented
with 30% of Matrigel, MA+ cells developed very few (less than 3
per well) and smaller colonies after 26 days of growth in
comparison with MP cells, whereas MA- cells developed
significantly more (.40 per well, p,0.05) and bigger (+50%
Figure 2. Effect of Arl2 content on three-dimensional cell growth. A: Soft agar and soft agar complemented with matrigel (30% v/v) assay for
MA-, MP and MA+ cells expressed in colonies number (left) and in area means (right). Bars represented standard deviations. Statistical significance
was determined using Student’s t test. B: Follow up of MA-, MP and MA+ cells overlayed on matrigel. Representative images displayed cellular
colonies growth from day 6 to Day 20 after cells seeding. C: Matrigel cluster assay performed for MdaA-, MdaP and MdaA+ cells. Light blue lines
represent the contour of cells clusters at day 2 and dark blue lines at day 5 after cells seeding (left, representative images). Mean rates of cluster
growth were evaluated by daily measurements of cell clusters areas from day 2 to day 5. Bars represented standard deviations. Statistical significance
was determined using Student’s t test.
doi:10.1371/journal.pone.0007478.g002
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suggested that MA- cells have a stronger, and MA+ cells a
weaker, clonogenic potential than MP cells.
MA-, MP and MA+ were also seeded on a Matrigel coat to study
their proliferative behavior in a three-dimensional extracellular matrix
( F i g u r e2 b ) .A f t e r6t o1 3d a y so fg r o wth, the three cell lines displayed
similarly growth properties with formation of small colonies. After 17
days of growth, the MA+ colonies began to disaggregate. After 20 days
of growth, MP colonies also began to disaggregate whereas MA-
colonies were still present, exhibiting a compact mass (Figure 2b).
These assays were not applicable to the MDA-MB 231 derived
cell lines because these cells did not develop isolated cellular
colonies in Matrigel or soft agar. We therefore studied the three-
dimensional growth capacity of MDA-MB 231 derived cells with
the Matrigel cluster assay (Figure 2c). This assay consists in loading
a compact cell cluster in a thick layer of Matrigel in order to follow
the growth capacity of a ‘‘tumor-like’’ cluster in a three
dimensional environment. For the first two days, no significant
differences between the three cell lines were observed. After day 2,
MdaA- cell clusters had a significant higher (+30%, p,0.05)
growth rate than MdaP and MdaA+ cell clusters.
Arl2 content influences tumor growth in vivo
We evaluated the tumorigenicity of the different MDA-MB 231
and MCF7-derived cell lines in SCID mice. MdaA-, MdaP,
MdaA+ cells were transfected with a plasmid encoding firefly
luciferase as described in the materials and methods section.
Resulting bioluminescent cell lines (MdaA-.luc, MdaP.luc,
MdaA+.luc) with bioluminescence in vitro were injected into the
mammary fat pad of SCID mice and monitored for tumor growth.
Bioluminescent measurements showed that the MdaA-.luc
derived tumors were significantly larger (+65% to 80%, p,0.05)
than those developed by MdaP.luc cells (Figure 3a). Conversely,
MdaA+.luc derived tumors were significantly smaller (245% to
55%, p,0.05) than those formed by MdaP.luc cells, resulting in a
large difference between MdaA-.luc and MdaA+.luc derived
tumors (+100–200%, p,0.01). In addition, the mean rate of
tumor growth (R-growth) was evaluated between days 17 and 36
(Figure 3b). Tumors derived from MdaA-.luc cells presented a
two-fold higher R-growth than MdaP.luc tumors which displayed
a 35% higher R-growth than MdaA+.luc tumors. Similar results
were obtained in MCF7 and non-bioluminescent MDA-MB 231
derived cells (data not shown).
Figure 3. Arl2 content influences tumorigenesis. A: Representative images of non invasive bioluminescent follow up (from day 17 to day 36) for
a same tumor of each cell lines (MdaA-.luc, MdaP.luc, MdaA+.luc) developed from mice mammary fat pad injected cells. B: Mean rates of tumoral
bioluminescence in mice expressed in photons/sec for each day and sublines. Tumor growths (R-growths) were evaluated using a linear projection of
the growth curve (red) and expressed in arbitrary units per day (AU/day). Bars represent standard deviations. Statistical significance was determined
using Student’s t test. C: Representative images of histochemistry of MdaA-, MdaP, MdaA+ cells tumors slides at day 22, 29 and 36. Black arrows show
necrotic regions (in light pink) which are particularly important in MdaA+ cells tumors.
doi:10.1371/journal.pone.0007478.g003
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Histopathology analyses showed that all MdaA+.luc tumors
presented a large necrotic area as early as day 22 post-injection.
These areas encompass 15% of the total tumor volume on day 22
and more than 70% on day 36. Conversely, MdaA-.luc tumors,
although much larger, contained much less necrotic areas,
representing a maximum of 25% of total tumor volume on day
36. MdaP.luc tumors displayed intermediate size necrosis. Similar
results were obtained with MA-, MP and MA+ cells (data not
shown). These differences in spontaneous necrosis were likely to
account at least in part for the differences observed in tumor
growth.
To determine whether PP2A activity was significantly different
according to Arl2 status during tumor growth in vivo, we measured
PP2A activity in tumors. As shown in Table 1, MA+ and MdaA+
cells displayed stronger phosphatase activity against the phospho-
serine substrate than their corresponding variants, MP and MdaP.
In MA- and MdaA- cells, PP2A activity was similar to that of the
control cells. These results suggest that Arl2 status modulates
PP2A activity in vivo.
Inhibition of Arl2 in vivo enhances tumor growth and
development of human breast cancer xenografts
We assessed the effect of Arl2 and PP2A inhibition in vivo on the
tumor growth of MDA-MB 231 cells. For this, we administered
duplex siRNAs directed against each of these targets intraperito-
neally five days a week for four weeks. Scrambled siRNA was used
as a control. Both siRNA against Arl2 and against PP2A were
found to enhance tumor growth in comparison to controls injected
with scrambled siRNA (Figure 4). These results strongly suggest
that Arl2 profoundly influences tumor cell aggressivity in vivo.A s
previously shown, inhibition of PP2A was also associated with
enhanced tumor aggressivity.
To confirm in vivo modulation of expression of target genes,
tumor and liver samples were obtained while mice were receiving
siRNA therapy. As shown in Table 2, gene expression of PP2A
and Arl2 was significantly and specifically repressed by the
corresponding siRNA both in liver and in tumors during therapy.
Expression levels of Arl2 in human primary breast tumors
Thirty eight primary breast tumors were available for analysis.
Arl2 mRNA content was determined after normalization with 18S
ribosomal RNA. Five primary tumors were associated with lymph
node involvement and four tumors were of larger size (T3 or T4 of
the TNM classification). When classifying tumors according to
Arl2 expression in primary tumors (lower or greater than median
in the entire group) we found that all of the large tumors (p=0.05,
Chi-square test) and all of the tumors with lymph node metastases
(p=0.03, Chi-square test) were found in samples with low Arl2
expression in the primary tumor (Table 3). Although these
observations should be confirmed on larger series, these data
suggest that tumors with low Arl2 content are more aggressive
clinically.
Discussion
Our results suggest that Arl2 content influences breast tumor
growth and aggressivity through a PP2A mediated pathway. In a
previous study we have demonstrated that Arl2 content influences
the content and the activity of the catalytic subunit of PP2A
(PP2Ac) [20]. Given the reported tumor suppressor properties of
PP2A [14], we have determined the impact of Arl2 on tumor cell
aggressivity and tumorigenic capacity in two breast cancer cell
models, MCF7 and MDA-MB-231. We observed that modifica-
tions of Arl2 expression levels could induce modifications of
contact inhibition, clonogenic potential, and tumor growth,
including spontaneous apoptosis of tumor cells. Preliminary data
also suggest that cells with reduced Arl2 content possess enhanced
metastatic potential when injected orthotopically in SCID mice
Table 1. PP2A activity measured using a phosphoserine
substrate in Arl2 variant lines.
PP2A activity
MA- 1,0216266
MP 9846204
MA+ 1,3526160
MdaA- 1,303682
MdaP 1,466635
MdaA+ 2,006667
Values represent the picomoles of phosphate issued after the
dephosphorylation of the above substrates and are denoted as mean 6
standard deviation.
doi:10.1371/journal.pone.0007478.t001
Figure 4. Effect of in vivo siRNA directed against Arl2 or PP2A
on human MDA-MB-231 xenografts. SCID mice were injected
subcutaneously on day 1 (black triangle) with MDA-MB 231 cells then
treated daily, 5 days a week for 4 weeks with siRNA (scrambled
continous line), directed against Arl2 (dotted line), directed against
PP2A (dashed line). *Significant differences were observed between the
groups receiving scrambled and Arl2 or PP2A directed siRNA (p,0.05).
Arrows represent siRNA injections.
doi:10.1371/journal.pone.0007478.g004
Table 2. Expression levels of Arl2 and PP2A of tumor and liver
samples in mice exposed to control siRNA, anti PP2A siRNA or
anti Arl2 siRNA.
PP2A (rt-
PCRunits)
PP2A (rt-
PCRunits)
Arl2 (rt-
PCR units)
Arl2 (rt-PCR
units)
Tumor Liver Tumor Liver
Control siRNA 0.3760.22 0.4760.16 5.9860.66 0.8060.11
Arl2 siRNA 0.3860.06 0.3060.02 0.2360.11* 0.0360.02*
PP2A siRNA 0.0660.03* 0.0660.01* 3.9464.15 0.6160.11
*: significantly different from control.
doi:10.1371/journal.pone.0007478.t002
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different breast cancer cell models, that a reduced Arl2 expression
level is associated with a more aggressive neoplastic phenotype.
These results were supported by the observation that low Arl2
content was associated with greater aggressivity in primary human
breast tumors.
Cells with reduced Arl2 content were found to behave more
aggressively, with loss of contact inhibition, ability to grow in
multilayer in vitro, enhanced clonogenic or cluster formation
potential, gain of survival advantage vis-a `-vis their normal
counterparts in an in vitro competition assay as well as enhanced
tumor growth and reduced spontaneous necrosis tumors in vivo.
The role of Arl2 downregulation in the acquisition of an aggressive
phenotype is supported by similar results observed when mice
injected with parental cells were treated with siRNA against Arl2.
This treatment effectively modulated Arl2 gene expression in
tumors and was associated with increased tumor growth.
Conversely increased expression yielded the opposite phenotype,
both in vitro and in vivo, with reduced clonogenic potential and
reduced tumor growth with massive spontaneous tumor necrosis.
These results therefore strongly suggest that Arl2 content is
correlated with in vitro and in vivo aggressivity in the two breast
cancer models studied.
PP2A has been shown to play an important inhibitory effect on
cell proliferation [22,23]. We have previously shown that the
content and the activity of the catalytic subunit of PP2A (PP2Ac) is
modified in cells with altered Arl2 content [20]. Here we confirm
that inhibition of PP2A in SCID mice is associated with increased
tumor aggressivity. Analysis of enzymatic activity in Arl2 modified
tumors showed that PP2A activity was increased in cells with
increased Arl2 content, a result in keeping with our observation
that these cells proliferated more actively in the presence of a
PP2A inhibitor. PP2A is known to interact directly with many
proteins and modify their activity by either activating or inhibiting
them. The anti-apoptotic proteins Bcl2 and Bcl-xl and the pro-
apoptotic proteins such as Bax are targets of PP2A. In these
proteins, the dephosphorylation occurs at the serine residues and
shifts the signaling pathway toward apoptosis by activating and
deactivating the pro- and anti-apoptotic proteins, respectively
[24]. The increased PP2A activity of cells with high Arl2 content is
thus likely to explain the massive apoptosis observed in tumors
derived from these cells. Conversely the enhanced aggressivity
observed in cells with reduced Arl2 content could not be attributed
to a reduction in PP2A enzyme activity.
It remains to be established which are the key regulators
involved in Arl2/PP2A regulation of tumor aggressivity. PP2A
dephosphorylates a large variety of substrates involved in cell cycle
regulation. Our previous study found that alterations in Arl2
content profoundly modified microtubule dynamics as well as the
duration of the various phases of mitosis, in particular anaphase
and telophase [20]. We have also reported that Arl2 content
influences the content and distribution of phosphor-ser15-P53
[21]. Moreover, other authors have recently demonstrated the
involvement of MT dynamics and of PP2A in the regulation of
concentration of E-cadherin at cell-cell contacts. Stehbens et al.
identified a pool of MTs that extend radially into cell-cell contacts,
blocking MT dynamics and thereby altering the ability of cells to
concentrate and accumulate E-cadherin at cell-cell contacts [25].
Takahashi et al. have shown that treatment of the cells with
inhibitors of PP2A caused disruption of cell-cell adhesion and
proposed that PP2A could play a crucial role in the maintenance
of cell-cell adhesion [26].
In conclusion these data suggest that Arl2, a small GTP protein
whose role is yet largely unknown, appears to be a significant
regulator of PP2A content and activity in breast cancer cells, both
in vitro and in vivo. In preclinical models, reduced Arl2 content is
associated with enhanced tumor aggressivity while increased Arl2
content is associated with reduced aggressivity and enhanced
spontaneous necrosis. In primary human breast tumors, low Arl2
mRNA content is associated with larger tumor size and greater
risk of lymph node involvement at diagnosis. These data suggest
that Arl2, possibly through a PP2A-mediated pathway, is a key
regulator of breast tumor aggressivity.
Materials and Methods
Ethics Statement
All research involving animals have been conducted according
to relevant national and international guidelines. The protocol was
approved by the Lyon Animal Experimental Committee and
animals were treated in accordance with European Union
guidelines for laboratory animal care and use.
Cell culture and transfection
All cell lines were grown in DMEM containing L-glutamine,
penicillin (200 IU/ml), streptomycin (200 mg/ml), and fetal bovine
serum (10%) at 37uC in the presence of 5% CO2. MCF-7 cells
were stably transfected with empty pcDNA3 (MP cells) or
pcDNA3 containing sense Arl2 (MA+ cells) or antisense Arl2
(MA- cells) as describe elsewhere [20]. The same experimental
strategy was used to obtain stable transfectants from MDA-MB
231 cells (commercial cell lines ATCC number HTB26), yielding
MdaP, MdaA+, and MdaA- cells. MdaP, MdaA+ and MdaA-,
cells were then co-transfected with plasmids expressing the firefly
luciferase gene (pGL3-basic, Promega) and the puromycin
resistance gene (pSuper/Puro; Oligoengine) using lipofectamine
(Invitrogen) according to the manufacturer’s recommendations,
and bioluminescent puromycin resistant cells were then selected.
The three bioluminescent derivatives cells named, MdaP.luc,
MdaA+.luc and MdaA-.luc were used for in vivo studies.
Determination of confluent cell proliferation rates
Cell proliferation was estimated using the methylthiazoletetra-
zolium (MTT) assay. Twenty thousand cells were seeded per well
of a 24-well plate and incubated at 37uC. Every 24 h up to 6 days,
MTT (500 mg/per well) was added to 3 wells of each plate. After
2 h of incubation at 37uC, supernatants were removed and
absorbance measured as described previously [27].
Cell cycle distribution by flow cytometry analysis
Cells were collected and incubated at 4uC during 2 h with 1 ml
of propidium iodide solution (0.05 mg/ml) containing Nonidet-
P40 (0.05%). Cells were analyzed using a FACS Calibur flow
Table 3. Tumor size and lymph node involvement in primary
human breast tumors according to Arl2 expression levels.
Tumor size Tumor size
Node
involvement
Node
involvement
T1/T2 T3/T4 Negative Positive
Low Arl2 12 4 11 5
High Arl2 13 0 13 0
Arl2 levels were determined by quantitative rt-PCR on frozen primary breast
tumors.
doi:10.1371/journal.pone.0007478.t003
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Modfit LT 2.0
TM software (VeritySoftware Inc, Topsham, United
States).
In vitro cell growth assays
All microscopic analyses were performed in the Centre
Commun de Quantime ´trie (Universite ´ de Lyon I, France), unless
otherwise stated.
Coculture cell competition assay. MP and MA- cells were
separately incubated with different fluorescent cell linker dyes
(respectively PKH 67 green and PKH 26 red (Sigma)) following
the manufacturer’s recommendations and were then placed in
coculture at a 1:1 ratio. A similar dye-swap experiment was
performed with PKH 67 green for MA- cells and PKH 26 red for
MP cells. Fluorescent images were taken at day 1 and 3 after cell.
Growth in soft-agar and soft-agar containing
matrigel. At the time of plating in soft-agar in 6-well plates,
2610
4 total cells were mixed with 1.5 ml of 0.45% low melting
point (LMP) agarose-DMEM (top layer) and then poured on top of
1.5 ml of solidified 0.75% LMP agarose-DMEM (bottom layer)
completed with 30% (v/v) matrigel (BD Biosciences) for the
matrigel-containing soft-agar condition. Colonies were counted
and photographed after 26 days in triplicate.
Overlay three-dimensional culture on matrigel. Overlay
three-dimensional cultures on matrigel (BD Biosciences) were
performed as described previously in triplicate [28]. 100 mlo f
matrigel were added in each well of an 8-well glass chamber slide.
For each cell line, a cellular suspension containing 12,500 cells/ml
in a medium containing 4% (v/v) matrigel was prepared. 400 mlo f
this mixture was plated per well on top of the solidified matrigel.
This corresponds to a final overlay solution of 5000 cells/well in
medium containing 2% matrigel. Cell colony formation was
monitored using microscopic observation and image acquisition
up to 20 days after incubation.
Matrigel cluster assay. For each of the MDA-MB 231
derived cell lines, a cellular suspension containing 1610
6 cells/ml
in DMEM medium was prepared. Matrigel (BDBiosciences) was
added to the wells of an 8-well glass chamber slide in a volume of
300 ml. Before matrigel polymerization, 1 ml containing 1610
6
cells was carefully loaded in the middle of the matrigel coating.
Then, matrigel containing preparations were allowed to solidify at
37uC and cells loading were formed a compact crowd of cells.
150 ml of complete medium were then added on wells containing
matrigel. Area of each cells cluster was determined for up to 5 days
using microscopic observation and quantified using ImageJ
software. Measurements were performed in triplicate.
Orthotopic tumorigenicity assays
For each cell line, five female SCID mice aged 4–6 weeks were
anesthetized and injected with 50 mlo f2 610
6 cells suspended in
50% DPBS/50% matrigel into the abdominal mammary fat pad.
The size of the tumor was measured twice a week by external
measurement or in vivo bioluminescent imaging. Mice were killed
when the tumors reached a greatest diameter of 1,2 cm. The
protocol was approved by the Lyon Animal Experimental
Committee and animals were treated in accordance with
European Union guidelines for laboratory animal care and use.
In vivo bioluminescent imaging was performed by administering
the substrate D-luciferin by intraperitoneal injection at 150 mg/kg
in D-PBS (Invitrogen), and anesthetized (1–3% isoflurane). Mice
were then placed inside a light-tight box under a photon counting
camera (NightOWL II LB 983, Berthold Technologies, Germany)
with continuous exposure to 1–2% isoflurane + 4% oxygene.
Regions of interest from displayed images were identified around
the tumor sites and were quantified as photons/s using WinLight
32
software (Berthold Technologies, Germany) with background
bioluminescence substraction. Tumor growth (R-growth) was
evaluated using a linear projection of the growth curve.
Pathological analysis of tumor clusters
After fixation in Bouin’s solution the tumor or cell cluster was
dehydrated with alcohol, immersed in xylene and embedded in
paraffin. Four mm-thick slides were dried at 58uC for 30 minutes in
an incubator. After deparaffination and rehydration, the paraffin
sections were stained with hematoxylin and eosin. The slides were
mounted with a xylene mounting medium.
siRNA administration in vivo
The siRNA were purchased from Sigma-Aldrich as duplex
desalted and deprotected non-modified sequences of 21 base pairs.
The sequences were the following: Arl2, 59-AACCCUCCUCAU-
CUUUGCUAA-TT; PP2Ac, 59- GAGGUUCGAUGUCCA-
GUUATT-TT, scrambled (SCR), 59- GCUGAUAGCAUGGU-
CUGAUTT-TT.
In this experiment, three groups of ten SCID mice were studied.
The groups I, II and III correspond respectively to the scrambled
siRNA, Arl2 siRNA and PP2Ac siRNA the injected mice. The first
day, 3 millions of MDA-MB 231 cells were implanted subcuta-
neously in all mice followed by intraperitoneal injections of SCR,
PP2A and Arl2 siRNAs (4 m in 50 ml of PBS). The injections of
siRNAs were continued daily for a period of four weeks and the
volumes of tumors were monitored twice per week till two weeks
after the end of injections.
Quantitative real-time RT-PCR
The level of inhibition exhibited by the Arl2 and PP2A siRNA
on their respective targets was assessed by real-time quantitative
PCR on tumors and livers extracted 24 hours after the last siRNA
injection. Total mRNA extraction, reverse transcription and real-
time quantitative RT-PCR were performed using a lightcylcer
thermal cycler (Roche, Manheim, Germany). Forward and reverse
primer sequences used for Arl2 were respectively 59-
GGCTCCTGACCATTCTGAAG and 39- TGTAGTTCTGG-
GACCTCGTG; for PP2Ac: 59- CCCTGGATCGTTTACAG-
GAA and 39- ATGGTAAAAGTCACGTGGGT. Results were
analyzed with RelQuant software (Roche, Manheim, Germany).
PP2A enzyme activity assay
The specific activity of the phosphatase PP2A was assessed using
a system based on the immunoprecipitation of PP2Ac (Upstate-
Millipore, USA) as recommended by the manufacturer by using
300 mg of total protein of each of the cell lines MA-, MP, MA+,
MdaA-, MdaP, MdaA+. The peptide containing a phosphorylated
threonine residue (K-R-pT-I-R-R) provided with the system was
replaced by a similar peptide containing a phophoserine residue
(K-R-pS-I-R-R), synthesized by Dr. Ficheux (IBCP Universite ´
Lyon 1) in order to better mimick the physiological situation. The
optical density of the products issued from the dephosphorylation
was read as an absorbance at 620 nm. The samples were
compared to a standard curve corresponding to a range of 0 to
2000 pmol of free phosphates. The values obtained for the cells
MP and Mda P were used as reference.
PCR analysis of primary breast tumors
Primary breast tumors were obtained from the Centre Le ´on
Be ´rard anti Cancer Tissue Bank. Patients gave written informed
consent for these analyses. Total mRNA was extracted with Trizol
Arl2 in Breast Cancer
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were converted into cDNA by Moloney leukaemia virus reverse
transcriptase (Invitrogen) as described in the manufacturer’s
manual. cDNA levels were normalized to the expression of 18S
ribosomal gene using the pre-developed TaqMan assay reagents
control kit (Applied biosystem, Foster City, Canada) and assayed
for Arl2 by real time PCR performed in a LightCycler thermal
cycler (Roche, Meylan, France) as previously described [20].
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